

**Amendments to the claims:**

This listing of claims will replace all prior versions and listing of claims in the application:

Listing of Claims:

Claims 1-20 (canceled).

Claim 21 (currently amended) A peptide or polypeptide or a fragment thereof comprising an Fv molecule, wherein said Fv molecule[[s]] comprises a heavy chain variable region and a light chain variable region, and  
~~a construct thereof, a fragment of either, or a construct of a fragment having enhanced binding characteristics so as to bind selectively and/or specifically to a target cell in favor of other cells, wherein the binding selectivity or specificity is primarily determined by a first hypervariable region,~~  
~~and wherein the Fv is a scFv or a dsFv, and optionally having one or more tags, and wherein the binding selectivity or specificity is secondarily influenced by a second hypervariable region, by a third hypervariable region, and/or by one or more of the upstream or downstream region flanking the first, the second and/or the third hypervariable regions, and wherein the second and third hypervariable regions are a CDR2 and CDR1 hypervariable region respectively and wherein the heavy chain variable region comprises CDR3, CDR2 and CDR1 regions~~ have comprising the amino acid sequences SEQ ID NOs:8, 115 and 114, respectively.

Claims 22-41 (canceled).

Please add the new claims:

Claim 42 (new) The peptide or polypeptide of claim 21, wherein the heavy chain variable region comprises CDR3, CDR2 and CDR1 regions consisting of the amino acid sequences SEQ ID NOs:8, 115 and 114, respectively.

Claim 43 (new) The peptide or polypeptide of claim 21, wherein the CDR3 region consists of SEQ ID NO:8.

Claim 44 (new) The peptide or polypeptide of claim 21, wherein the CDR2 region consists of SEQ ID NO:115.

Claim 45 (new) The peptide or polypeptide of claim 21, wherein the CDR1 region consists of SEQ ID NO:114.

Claim 46 (new) The peptide or polypeptide of claim 21, wherein the peptide or polypeptide binds one or more cell types selected from the group consisting of cancer cells and cells expressing glycolalicin.

Claim 47 (new) The peptide or polypeptide of claim 46 wherein the cancer cells are selected from the group consisting of carcinoma, sarcoma, leukemia, adenoma, lymphoma, myeloma, blastoma, seminoma, and melanoma cells.

Claim 48 (new) The peptide or polypeptide of claim 47 wherein the leukemia cells are selected from the group consisting of B lineage leukemia cells, T lineage leukemia cells, and myeloid lineage leukemia cells.

Claim 49 (new) The peptide or polypeptide of claim 48 wherein the B lineage leukemia cells are selected from the group consisting of B-CLL and B-ALL.

Claim 50 (new) The peptide or polypeptide of claim 48, wherein the myeloid lineage leukemic cells are selected from the group consisting of CML and AML.

Claim 51 (new) The peptide or polypeptide of claim 46 wherein the cells expressing glycolalicin are platelets.

Claim 52 (new) The peptide or polypeptide of claim 42, wherein the scFv has a light chain variable region consisting of SEQ ID NO:7.

Claim 53 (new) An scFv consisting of SEQ ID NO:25.

Claim 54 (new) An scFv consisting of SEQ ID NO: 208.

Claim 56 (new) An scFv consisting of SEQ ID NO: 235.